Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
3.60 x 1 3.62 x 1
Post-market by (Cboe BZX)
3.63 +0.19 (+5.52%) 03/27/25 [NASDAQ]
3.60 x 1 3.62 x 1
Post-market 3.61 -0.02 (-0.55%) 16:36 ET
Quote Overview for Thu, Mar 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.42
Day High
3.66
Open 3.45
Previous Close 3.44 3.44
Volume 7,407,976 7,407,976
Avg Vol 11,565,089 11,565,089
Stochastic %K 23.54% 23.54%
Weighted Alpha -75.79 -75.79
5-Day Change +0.09 (+2.54%) +0.09 (+2.54%)
52-Week Range 3.33 - 15.18 3.33 - 15.18
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,127,897
  • Shares Outstanding, K 327,877
  • Annual Sales, $ 164,070 K
  • Annual Income, $ -372,180 K
  • EBIT $ -395 M
  • EBITDA $ -362 M
  • 60-Month Beta 0.93
  • Price/Sales 6.95
  • Price/Cash Flow N/A
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 158.96% ( +12.78%)
  • Historical Volatility 80.44%
  • IV Percentile 78%
  • IV Rank 25.16%
  • IV High 520.68% on 03/13/25
  • IV Low 37.36% on 08/15/24
  • Put/Call Vol Ratio 0.34
  • Today's Volume 3,189
  • Volume Avg (30-Day) 7,295
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 137,652
  • Open Int (30-Day) 191,012

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 6
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +40.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.33 +9.01%
on 03/26/25
Period Open: 5.26
4.57 -20.57%
on 03/03/25
-1.63 (-30.99%)
since 02/27/25
3-Month
3.33 +9.01%
on 03/26/25
Period Open: 7.37
8.15 -55.46%
on 01/02/25
-3.74 (-50.75%)
since 12/27/24
52-Week
3.33 +9.01%
on 03/26/25
Period Open: 14.10
15.18 -76.09%
on 03/28/24
-10.47 (-74.26%)
since 03/27/24

Most Recent Stories

More News
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval...

IOVA : 3.63 (+5.52%)
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not

The time to buy quality prospects is when the rest of the market is ignoring their value.

IOVA : 3.63 (+5.52%)
PEP : 149.67 (+0.69%)
SIRI : 23.82 (-0.54%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA : 3.63 (+5.52%)
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?

When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play. A stock that...

IOVA : 3.63 (+5.52%)
Iovance Biotherapeutics: Q4 Earnings Snapshot

Iovance Biotherapeutics: Q4 Earnings Snapshot

IOVA : 3.63 (+5.52%)
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

IOVA : 3.63 (+5.52%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA : 3.63 (+5.52%)
My 3 Favorite Stocks to Buy Right Now

The market's underestimating how well each of these companies should be able to capitalize on their opportunities.

IOVA : 3.63 (+5.52%)
AXON : 550.65 (-1.50%)
UBER : 74.86 (+0.92%)
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

IOVA : 3.63 (+5.52%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA : 3.63 (+5.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 3.72
2nd Resistance Point 3.62
1st Resistance Point 3.53
Last Price 3.63
1st Support Level 3.34
2nd Support Level 3.24
3rd Support Level 3.15

See More

52-Week High 15.18
Fibonacci 61.8% 10.65
Fibonacci 50% 9.26
Fibonacci 38.2% 7.86
Last Price 3.63
52-Week Low 3.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies